Atlas Trials

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Clinical trial NCT01973660 · COMPLETED

Trial details

NCT number
NCT01973660
Sponsor
SOLTI Breast Cancer Research Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2013-10-01
Primary completion
2016-06-01
Enrollment
151

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.